

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/082,973	(02/26/2002	James S. Norris	14017-004002 /PSU 96-1566	8113	
26161	7590	03/08/2005		EXAM	EXAMINER	
FISH & RIC 225 FRANK		SON PC		EPPS FORD	, JANET L	
BOSTON, 1	_	0		ART UNIT	PAPER NUMBER	
, , , ,				1635		

DATE MAILED: 03/08/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

F								
,	Application No.	Applicant(s)						
Advisory Action	10/082,973	NORRIS ET AL.						
Before the Filing of an Appeal Brief	Examiner	Art Unit						
	Janet L. Epps-Ford, Ph.D.	1635						
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address -						
THE REPLY FILED 14 December 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.								
1. The reply was filed after a final rejection, but prior to filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:								
 a) The period for reply expires months from the mailing of the period for reply expires on: (1) the mailing date of this Adversent, however, will the statutory period for reply expire later the 	isory Action, or (2) the date set forth in th		ter. In no					
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).								
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened sta above, if checked. Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	which the petition under 37 CFR 1.136(a and the corresponding amount of the fee. atutory period for reply originally set in the	The appropriate extension fee usinal Office action; or (2) as set	under 37 t forth in (b)					
2. The reply was filed after the date of filing a Notice of App was filed on 14 December 2004 . A brief in compliance we the Notice of Appeal (37 CFR 41.37(a)), or any extension Notice of Appeal has been filed, any reply must be filed water AMENDMENTS.	vith 37 CFR 41.37 must be filed wit in thereof (37 CFR 41.37(e)), to avo	hin two months of the date id dismissal of the appeal.	of filing					
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because								
(a) \boxtimes They raise new issues that would require further consideration and/or search (see NOTE below); (b) \square They raise the issue of new matter (see NOTE below);								
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or								
(d) They present additional claims without canceling a		jected claims.						
<u> </u>	NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).							
5. Applicant's reply has overcome the following rejection(s		omphant Amendment (FTC	JL-324).					
6. Newly proposed or amended claim(s) would be a	6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling							
the non-allowable claim(s). 7. ☑ For purposes of appeal, the proposed amendment(s): a) ☑ will not be entered, or b) ☐ will be entered and an explanation of								
how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed:	vidèd below or appended.							
Claim(s) objected to: Claim(s) rejected: <u>1,4,5,7,10,12,17,19-24,26,35,36 and 3</u>	88 would remain rejected for the re	asons of record .						
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE								
8. The affidavit or other evidence filed after a final action, b because applicant failed to provide a showing of good ar and was not earlier presented. See 37 CFR 1.116(e).								
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to a showing a good and sufficient reasons why it is necessar The affidavit or other evidence is entered. An explanation 	overcome <u>all</u> rejections under appery and was not earlier presented.	al and/or appellant fails to See 37 CFR 41.33(d)(1).						
REQUEST FOR RECONSIDERATION/OTHER		•						
11. The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application i	n condition for allowance b	ecause:					
12. ☐ Note the attached Information Disclosure Statement(s).13. ☐ Other:	(PTO/SB/08 or PTO-1449) Paper	No(s). <u>11-18-2004</u>						
		Janet L. Epps-Ford, Ph.(Patent Examiner	D.					

U.S. Patent and Trademark Office PTOL-303 (Rev. 9-04)

Art Unit: 1635

Continuation of 3. NOTE: Applicant's amendment to the claims to insert wherein the nucleotide sequence is operably linked to a tissue-specific promoter raises new grounds of rejection under 35 USC § 102(e) and 102(a) or § 103(a) over Norris et al. US 5,824,519, and WO 98/24925. Applicants previously amended the instant claims to remove the limitation "tissue-specific promoter," and have added wherein the autocatalytically cleaving ribozyme comprises a first and second complementary arm, wherein one of the arms is longer than the corresponding arm of a pCLIP cassette. In response the examiner withdrew the prior art rejections over the Norris et al. references. Applicant's amendment to claims filed 12-14-2004 reintroduces the tissue-specific promoter limitation, Norris et al. discloses a modified pClip cassette comprising a tissue specific promoter, an autocatalytically cleaving riboxyme comprising complementary arms, wherein one of the arms is longer than the corresponding arm of the original pCLIP cassette, see Figure 3.

Continuation of 5. Applicant's reply has overcome the following rejection(s): Applicants response has overcome the Double patenting rejection and written description rejection set forth in the Final Rejection mailed 6-15-04.

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's amendment to the claims potentially raises new grounds of rejection (see continuation of item # 3) and would require a new search and consideration of the prior art.

JOHN L. LEGUNADER

SUPERVISO/TY PATENT EXAMINER

TECHNOLOGY CENTER 1600